Announced Tue, 7 Jul · 18:25 IST
Routine SEBI Regulation 74(5) compliance certificate for Q1 FY27
Compliance View source PDF
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.3%1-day move
₹388.95
prior close
₹385.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+0.6+0.6—+2.3+2.2+1.7+4.3+8.6+7.6————
Up moveDown movePending
AI summary
Aarti Drugs filed a routine SEBI Regulation 74(5) compliance certificate for Q1 FY27. Registrar MUFG Intime India confirmed that share certificates received for dematerialization during the quarter ended June 30, 2026 were processed, the underlying shares remain listed on BSE and NSE, mutilated certificates were cancelled after verification, and the depository was recorded as the registered owner within prescribed timelines. No material business or financial information is disclosed.
Likely market impact
No material impact. This is a standard quarterly compliance filing required by SEBI. Shareholders and the stock price are unaffected.